08.06.2015
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 Further Expands R&D Activities and Gains Important Insights in Stem Cell Research
DGAP-News: Vita 34 AG / Key word(s): Miscellaneous
Vita 34 Further Expands R&D Activities and Gains Important Insights in
Stem Cell Research
08.06.2015 / 07:33
---------------------------------------------------------------------
Vita 34 Further Expands R&D Activities and Gains Important Insights in Stem
Cell Research
Leipzig, June 08, 2015 - Vita 34 AG (WKN A0BL84), a pioneer in the storage
of stem cells from umbilical cord blood and tissue, and a specialist in
cryo-preservation, is increasing its research activities in the field of
biotechnology with new research projects. The intensification of R&D
activities is an important cornerstone of our corporate strategy: With new
discoveries in stem cell research Vita 34 is creating the prerequisites for
developing innovative new products, and thus the ability to achieve further
growth.
Beginning in fiscal year 2014 Vita 34 started a development project on the
cryo-preservation of autologous fatty tissue in its own research laboratory
in cooperation with domestic partners. Within the scope of this project
Vita 34 was able to isolate cells capable of division in fatty tissue,
among them mesenchymal stem cells. Thus, an important milestone on the way
to developing a process for cryo-preservation of the stem cells contained
in fatty tissue has been reached. Vita 34 plans to make these
anti-inflammatory mesenchymal stem cells via cryo-preservation available
for repeated use, for example in the treatment of arthritis.
Dr. André Gerth, CEO of Vita 34 AG, commented: "Enormous progress has been
made in biomedical research when it comes to cell-based therapies. With the
development of stem cell therapies, we expect an increasing need for the
safe storage of cells and tissues in the future. Vita 34 is making an
important contribution towards the further development of stem cell
medicine with this research project on the cryo-preservation of stem cells
from fatty tissue."
Overall, the Vita 34 research activities this year and in the coming two
fiscal years is being supported by EU, German Federal and State grants
amounting to nearly EUR 1.6 million. This significantly bolsters the Vita
34 research budget and multiplies the effect of own resources used.
Vita 34 gained important insights in an additional research project
together with the University of Leipzig. The objective was to determine how
a mesenchymal stem cell preparation from the umbilical cord needs to be
prepared, such that it can be employed most effectively for treating GvHD
(Graft vs. Host Disease).
In addition, Vita 34 is currently testing the effect of plant stem cells on
the vitality of human stem cells. The goal of this research project is to
develop a cream based on plant stem cells for improved regeneration of the
skin.
"The expansion of research initiatives is a significant part of the growth
strategy outlined by Vita 34. Via successful research, Vita 34 can open up
the potential of establishing new products based on stem cells in the field
of regenerative medicine, thereby earning additional revenue. We want to
take advantage of this opportunity and have taken a broad approach in our
research & development with targeted projects", explained Dr. Gerth.
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood and cord tissue. The basis
for its successful work is an outstanding position in the technological
segment of cryo-preservation. Here, cells and tissue are preserved alive at
some -190ºC for long periods of time, and can be used if needed in the
context of medical treatment. More than 125,000 families are already taking
advantage of this offering and have provided for their children with a stem
cell deposit at Vita 34.
---------------------------------------------------------------------
08.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
365939 08.06.2015
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V